109 related articles for article (PubMed ID: 12705787)
1. Molecular cancer therapeutics: recent progress and targets in drug resistance.
Tsuruo T
Intern Med; 2003 Mar; 42(3):237-43. PubMed ID: 12705787
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Tsuruo T; Naito M; Tomida A; Fujita N; Mashima T; Sakamoto H; Haga N
Cancer Sci; 2003 Jan; 94(1):15-21. PubMed ID: 12708468
[TBL] [Abstract][Full Text] [Related]
3. The proteasome, a new target for cancer therapy.
Gillessen S; Groettup M; Cerny T
Onkologie; 2002 Dec; 25(6):534-9. PubMed ID: 12566898
[TBL] [Abstract][Full Text] [Related]
4. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
[TBL] [Abstract][Full Text] [Related]
5. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy.
Loo TW; Clarke DM
FASEB J; 1999 Oct; 13(13):1724-32. PubMed ID: 10506575
[TBL] [Abstract][Full Text] [Related]
6. Deadly encounter: ubiquitin meets apoptosis.
Jesenberger V; Jentsch S
Nat Rev Mol Cell Biol; 2002 Feb; 3(2):112-21. PubMed ID: 11836513
[TBL] [Abstract][Full Text] [Related]
7. Role of proteasomes in T cell activation and proliferation.
Wang X; Luo H; Chen H; Duguid W; Wu J
J Immunol; 1998 Jan; 160(2):788-801. PubMed ID: 9551914
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
10. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
12. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.
Riesterer O; Zingg D; Hummerjohann J; Bodis S; Pruschy M
Oncogene; 2004 Jun; 23(26):4624-35. PubMed ID: 15064712
[TBL] [Abstract][Full Text] [Related]
13. PI3K/Akt signalling pathway and cancer.
Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
[TBL] [Abstract][Full Text] [Related]
14. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
[TBL] [Abstract][Full Text] [Related]
16. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Aldonza MB; Hong JY; Lee SK
Exp Mol Med; 2017 Jan; 49(1):e286. PubMed ID: 28104912
[TBL] [Abstract][Full Text] [Related]
18. Targeting PI3K-AKT pathway for cancer therapy.
Lu Y; Wang H; Mills GB
Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
[TBL] [Abstract][Full Text] [Related]
19. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
20. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
Kandasamy K; Srivastava RK
Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
